* 香港富豪李嘉诚旗下和黄医药0013.HK周五早盘涨3.1%。
* 该公司此前公告称，爱优特和达伯舒联合疗法的新药上市申请获中国国家药监局批准，用于治疗既往接受血管内皮生长因子受体-酪氨酸激酶抑制剂治疗失败且一线未接受程序性死亡受体-1或程序性死亡配体-1抑制剂的局部晚期或转移性肾细胞癌患者。
* 和黄医药今年迄今跌6%，同期恒生指数.HSI下滑0.2%。
* 恒⽣⽣物科技指数.HSBIO盘中一度升1.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 杨淑祯)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.